+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 40Years +
All Genders
ID07868419

Evaluating Nalbuphine Extended-Release Tablets Versus Placebo to Treat Chronic Cough in Idiopathic Pulmonary Fibrosis

Led by Trevi Therapeutics · Updated on 2026-10-09

201

Participants Needed

4

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of Nalbuphine Extended-Release NAL ER tablets for treating chronic cough in people with Idiopathic Pulmonary Fibrosis IPF. This Phase 3 study aims to compare NAL ER with a placebo to better understand its impact on cough frequency and severity in this condition. Participants will first complete a 2-week blinded dose adjustment period, then continue with a fixed dose of NAL ER 54 mg twice daily or a matching placebo for 12 weeks. The study is randomized and double-blind, meaning neither the participants nor the researchers know who receives the active drug or placebo during the trial. During the study, participants will be monitored for changes in 24-hour cough frequency, cough severity, respiratory symptoms, quality of life, and patient-reported impressions. Safety will be assessed by tracking any adverse events through Week 17. The total participation duration includes the 14-week treatment and follow-up period to evaluate both efficacy and safety outcomes.

CONDITIONS

Brief Title

Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets

Research Team

P

Paula Buckley

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here